rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial

Noor Sabagha RPH, MPH - NIH StrokeNet Clinical Research Pharmacist
Christian Unger PharmD, StrokeNet Clinical Research Pharmacist

Heather Maddison, Canadian Primary Blood Bank Technologist - Canadian Central Blood Bank
Joanne Lambley, MSc – Canadian Coordinating Centre

Prior to Readiness Call/SIV

Complete site Pharmacy regulatory

Receive study drugs

Readiness call

(Ask questions!)

Site Pharmacy Regulatory in WebDCU™

- Drug Destruction Policy/SOP or explanatory Note to File must be provided by site to Canadian Coordinating Centre (CCC) and uploaded into WebDCU™ by CCC.
- Canadian sites are not required to use Pharmacy. Sites not using Pharmacy will provide Health Canada Division 5 Certifications for study personnel delegated responsibilities “maintain accountability” and “dispense”. CCC will upload certificates and explanatory Note to File to WebDCU™.
- Drug shipping address must be provided by site to CCC, who will enter it into WebDCU™.
- The DOA will include at least one qualified person with the delegated task “maintain accountability”.
- When a Clinical Performing Site (CPS) is released to receive study drug, an initial study drug shipment will automatically be submitted to the Canadian Central Blood Band (CCBB) by WebDCU™.
- CCBB ships study drug kits a few days prior to readiness call/SIV to be received by site 1-2 days prior to call/SIV.
- CCBB will ship study drug kits Monday through Wednesday for next day delivery Tuesday through Thursday. No shipments will take place for receipt on Friday, Saturday, Sunday, or holidays, except under extenuating circumstances.

WebDCU™ Study Drug Shipping Email



WebDCU™ Email Notification

Study Drug Shipping

FASTEST study drug kit **#** was shipped to: **Site Name** on **date and time** .

Please confirm you received this kit in WebDCU.

This email was generated by Brittany GEBELT.
For more information, log on to the WebDCU study website. Powered by the Data Coordination Unit at the Medical University of South Carolina, USA.

Confidentiality Notice:
This email contains confidential information belonging to the sender, which is legally privileged. This information is intended for the use of the individual or entity(ies) named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of the contents of this email information for any purpose whatsoever is strictly prohibited. If you have received this email material in error, please notify us at the above telephone or email address **IMMEDIATELY** to arrange for the return or destruction of the emailed documents.

Intended For Use of Addressee Only:
This information has been disclosed to you from confidential records, which are protected by State Law and HIPAA regulations. These laws and regulations prohibit you from making any further disclosure of this information without the specific written consent of the person to whom it pertains, or as otherwise permitted by law. A general authorization for the release of medical or other information is not sufficient authorization for further disclosure of information, which is protected by Title 42 of the Code of Federal Regulations and other laws. Any unauthorized further disclosure in violation of the above may result in a fine or jail sentence or both.

- CPSs will receive an automated email from WebDCU™ for every study drug kit that was processed out of WebDCU™ for shipment.
- For example, if a shipment has 4 study drug kits in the shipment, the CPS will receive an individual email for each kit (4 emails).

NIH StrokeNet
PREVENTION | TREATMENT | RECOVERY

FASTEST

FedEx® Shipping Notification Email

- Site will also receive an email from FedEx® that includes a tracking number and any updates to shipment during transit for every shipment.

- The email will be sent to the Primary Study Coordinator unless the site indicates otherwise. Please email fastestbloodbank@ohri.ca or jlambley@ohri.ca if this is the case.

Study Drug Packaging and Packing Slip

Study drugs will be shipped refrigerated

Study drug kits will be shipped in a 6L or 12L insulated shipper, with a USB temperature logger, cold packs, and enough insulation to maintain a temperature range of 2-25°C for at least 24 hours. Kits will be sent via FedEx® overnight shipping.

Insulated Shipping Container

Temp-Tale



FASTEST Investigational Product Packing Slip

Ship From:
Canada Pharmacy
501 Smyth Road, Transfusion Medicine Room M3604
Ottawa, ONK1H 8L6

Contact: Heather Maddison
Phone: 613-737-8899 x71605

Ship To:
WebDCU Test Site 2, Charleston, SC
, SC

Shipment Tracking Number: 2348-08/06/2021

FASTEST Investigational Product Shipping Contents

Site ID: 2348 Site Name: WebDCU Test Site 2, Charleston, SC

No.	Drug Kit Code	rFVIIa/Placebo Component Code	Histidine Component Code	Expiration Date	Shipping Date
1	60001	2370094	2371896	1/21/2022	8/6/2021

Generated by WebDCU on 8/6/2021 12:58:43 PM EST

Back to previous page

Packing Slip

NIH StrokeNet
PREVENTION | TREATMENT | RECOVERY

FASTEST

Canadian Kit Label

Study Drug Kit ID

Verification code

Investigational Drug Protocol / Drogue de recherche

FASTEST TRIAL

Sponsor: Ottawa Hospital Research Institute
1053 Carling Avenue, Ottawa ON K1Y4E9

This kit contains:	Ce kit contient:
▪ Two recombinant Factor VIIa 5mg or Placebo 5mg vials ▪ Two histidine solvent 5.2ml prefilled syringes ▪ Two 13mm vial adaptors ▪ Dosing/compounding Card. Storage temperature: 2°-25° Celsius Expiration date is available in WebDCU™ at https://webdcu.musc.edu. Caution: To be used by qualified investigators only	▪ Deux flacons de facteur VIIa recombinant 5mg ou de placebo 5mg ▪ Deux seringues préremplies de 5.2ml de solvant d'histidine. ▪ Deux adaptateurs de flacon de 13mm ▪ Carte de dosage et de préparation. Température de conservation: 2°-25° Celsius Date de péremption est disponible sur https://webdcu.musc.edu. Reservee uniquement a l'usage de chercheurs competent

Study Drug Kit Box
Size: 19.5 cm x 16 cm x 5 cm



- Country-specific **blinded kit labels**
- Kits are tampered evident sealed**. <u>It is required not</u>** to break the tamper evident seal until the kit is dispensed.

Study Drug Receipt

- The initial study drug shipment will contain a total of two study drug kits to sites with one enrolling location (ED or MSU) and four study drug kits to sites that have two enrolling locations (ED+MSU) or 2 EDs
- Upon receipt of the drug shipment, the CPS will verify the receipt of the study drug kit(s) against the packing slip
- The site will review the temperature data from the logger and confirm that the study drug did not experience any temperature excursions in transit (next slide)
- Study drug kits cannot be dispensed until received into WebDCU™ **and** site is released to enroll

Example Data Logger Report



SENSITECH
United Technologies
SUPPLY CHAIN VISIBILITY

TempTale® Ultra

Serial #: GHZQN016F0

Alarm Status

OK

Monitor Configuration

Start Up Delay:	1 hr	Interval:	5 min

Monitor Read

On :	06-NOV-2019 7:31:48 PM	By :	TempTale®Ultra
Note:	All Times in GMT		

Recorded Data

First Point:	05-NOV-2019 8:50:53 PM
Stop Time	06-NOV-2019 6:51:20 PM
Number of Points:	265
Trip Length:	22 hr 5 min

Summary Data

Low Extreme:	2.9 °C @ 06-NOV-2019 5:35:53 AM
High Extreme:	7.8 °C @ 05-NOV-2019 8:50:53 PM
Mean ± Std Deviation:	3.6 °C ± 1.0 °C
Mean Kinetic Temperature:	3.7 °C
Activation Energy:	83.144 kJ/mol

Alarm Summary

Alarm Data

Alarm	Alarms Settings	Degree Minutes	Threshold (Type)	Total Time	Number of Events	Triggered	Status
Ideal range	>=2.0 °C <=8.0 °C	--	Unlimited	0 d 22 h 5 m	1	--	--
Alarm 1	Over 8.0 °C	0.0 °C min	0 d 0 h 5 m (S/E)	0 d 0 h 0 m	0	--	OK
Alarm 2	Under 2.0 °C	0.0 °C min	0 d 0 h 5 m (S/E)	0 d 0 h 0 m	0	--	OK

Originator Notes:

1. Once the data logger arrives at the CPS ➡ stop the data logger by pressing the red STOP button for 1-3 seconds until the stop sign logo appears in the top right corner of the LCD display.

2. Insert the data logger into a USB port of a computer at the CPS.

3. View the PDF temperature data log and review the data log for temperature excursions.

4. Print and file the temperature data log in the FASTEST trial binder to be available during monitoring visits.

5. Once the data has been retrieved from the logger and the temperature curve is printed, the temperature logger can be disposed of per the institution's policy.

6. If **NO** temperature excursions or discrepancies are identified, the CPS will confirm receipt of all study drug kits in WebDCU™ Drug Tracking>Drug Receiving.

FASTEST

Drug Tracking



NIH StrokeNet
PREVENTION | TREATMENT | RECOVERY

FASTEST

Receiving Drug



WebDCU FASTEST

Logan SIRLINE Sign Out

Edit: Drug Kit Site Receiving

Help

No.	Item Description	Data Value
2	Site name	WebDCU Test Site 2, Charleston, SC
3	Drug kit code	
6	Expiration date	
7	Date shipped	
8	Receiving status	○ Pending ◉ Confirm received ○ Lost in shipping
10	Date received	(dd-mmm-yyyy)
11	Verify code	
12	Receiving notes	(250 char.)
13	Receiving status reported by	*(to be assigned by the system)*
14	Receiving status reported on	*(to be assigned by the system)*

Last updated by Heather MADDISON on 06-Aug-2021 12:58PM

Save Record Cancel Edit

- If study drug kit(s) are not received into WebDCU™ **within 3 days** of shipment, the CPS will receive an automated email notification prompting them to receive the study drug kit(s) in WebDCU™

FASTEST

Study Medication Storage/Shipping Conditions

NOVO

- Novo Nordisk A/S will be shipping to the Canadian Central Blood Bank at 2-8°C

Canadian Central Blood Bank

- **Storage and shipping:** Study medication stored and will be shipped refrigerated.

Clinical Performing Sites

- **Storage:** Study medication can be stored (without preference) at room temperature or refrigerated; however, temperature **MUST** be **continuously monitored.**
- The permitted range for Canada: 2-25°C
- Sample temperature monitoring logs will be provided and available in WebDCU™
  - Toolbox>Project Documents

FASTEST

Temperature Monitoring Log Example

CPSs are required to **maintain continuous temperature monitoring** logs at each enrolling location

Sample temperature monitoring logs will be provided and available in WebDCU™
Toolbox>Project Documents



FASTEST

Investigational product (IP) Temperature Log
Trial: rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial
Canadian Protocol Number: 20200658-01T
Storage Temperature Range: at 2-25°C

Site Number:	Site PI:
Health Canada Sponsor: Dr. Dowlatshahi, Ottawa Hospital Research Insitute	Site Coordiantor:
	Month-Year:

Instructions: *Next to the appropriate date record time of the temperature reading, the current temperature, minimum temperature, maximum temperature, conformation of resetting of the thermometer (f applicable)and intials. Report any excursions promptly to study sponsors.*

Date	Time of Reading (24 hour clock)	Current Temp (°C)	Minimum Temp (°C)	Maximum Temp (°C)	Confirmation of Reset of Reading	Reader's Initials
1						
2						
3						
4						
5						
6						
7						
8						
9						
10						
11						
12						
13						
14						
15						
16						
17						
18						
19						
20						
21						
22						
23						
24						
25						
26						
27						
28						
29						
30						
31						

Verifying Reader

Printed Name	Signature	Initials

NIH StrokeNet
PREVENTION | TREATMENT | RECOVERY

FASTEST

Temperature Excursions

A temperature excursion occurs when **in-transit or on-site drug storage** temperatures fall outside of acceptable temperature ranges.

- A temperature excursion should be reported if storage temperature falls below 2°C and/or rises above 25°C.
- US Pharmacopeia (USP) rounding rules do apply for the temperature excursion, i.e., 1.5°C is rounded up to 2°C, and 25.4°C is rounded down to 25°C. Both examples are **not** reportable excursions.
- Any temperature excursion affecting FASTEST study drug kits must be reported immediately, preferably within **48 hours** of occurrence.

In Transit Temperature Excursion: If study drug experiences a temperature excursion in-transit, do NOT receive kits into WebDCU™ inventory. Study drug kits are available for randomization once they are marked as received in WebDCU™.

Reporting Temperature Excursions to Novo Nordisk A/S at **Site**



Quarantine in the appropriate storage temperature

(TDRF B) – Dispensed DUNs:
only to be used in the rare cases where a temperature deviation occurs, but action is not immediately taken to resolve this, and products are dispensed to patients

fastestbloodbank@ohri.ca

NIH StrokeNet
PREVENTION | TREATMENT | RECOVERY

FASTEST

Temperature Deviations



Temperature Deviation Report Form A – Site

Instructions:

- Please complete the form in its entirely. Fields marked with * are mandatory.
- Green text is guidance text and should be deleted before use.
- Email this form and all relevant temperature logs to NCC Central Pharmacy, at FASTESTtrialRX@ucmail.uc.edu
- US Pharmacopeia (USP) rounding rules apply for temperature excursions. i.e. 1.5°C is rounded up to 2°C and 8.4°C is rounded down to 8°C. Both examples are not a reportable excursion.

General information

*Trial ID: U1111-1201-0087/ FASTEST	*Site number:
*Country:	*Prioritisation date eg, next dispensing date or DBL date: Not known or N/A ☐
*Has the product affected by the deviation been dispensed to subjects?	Yes ☐ No ☐ If **no**, please complete Temperature Deviation Report Form B (**Page 2 of this document**) If **yes**, please complete Temperature Deviation Report Form B, Dispensed DUNs. (**Page 3 of this document**)
*Type of deviation Storage deviation : ☐ Attach graph/ logs Shipment deviation: ☐ Attach graph/ logs	Logger ID: Logging interval for storage temperature monitoring device Logger ID:

Description of the deviation

*Date/period of deviation Include time if relevant Start date/time: Stop date/time:	*Temperature Too warm: ☐ Too cold: ☐ compared to allowed temperature range Highest/lowest temperature:

Additional information: Only if relevant to the case evaluation, for example arrival time of the products if the temperature deviation is due to data logger not stopped upon arrival

Example: Above 30° for 45 min
Below 2° for 120 min

*It is confirmed that the products are stored, quarantined and within allowed temperature range.

Initials: Date:

- Fill in TDRF-A



Temperature Deviation Report Form B – Site

Green text is guidance text and should be deleted before use.

Please complete the form electronically and submit with the TDRF A. Fields marked with * *must* be completed.

Trial and site information

*Trial ID: U1201-0087/ FASTEST	*Site number: For example, "102"

Trial product information

*IWRS used	Yes ☐ No ☒
*If IWRS is used: Affected product status has been changed to "temporarily unavailable" in the IWRS.	Yes ☐ N/A ☒

Specific for deviations during shipment

* Shipment tracking no:	

*Please list all trial products involved in the deviation

*Product name	*Lot no/coded Lot no (if applicable)	*Kit (list all Kits for the specific lot)	*DUN/component code no (list all DUN for the specific batch)

Specific for deviations during storage

*Please list all trial products involved in the deviation

*Product name	*Lot no/coded lot no (if applicable)	*Shipment no	*Kit (list all kits for the specific lot)	*DUN/ component code no (list all DUN for the specific batch)

- Fill in TDRF-B

- Fill in TDRF-B, Dispensed DUNs



Temperature Deviation Report Form B, Dispensed DUNs – Site

Green text is guidance text and should be deleted before use.

Please complete the form electronically and submit with the TDRF A. Fields marked with * *must* be completed.

Trial and site information

*Trial ID: U1201-0087/ FASTEST	*Site number: For example "102"

*Please list all trial products involved in the deviation

*Product name	*Lot no/coded lot no (if applicable)	*Shipment no	*kit (list all Kits for the specific lot)	*DUN (list all DUNs for the specific kit)	*Date dispensed

Trial ID: U1201-0087/FASTEST
Site number: Unique description
Country:
Prioritisation date: Optional
Dispensed: Yes/No
Type: Storage/shipment
Logger ID: From Log or device
Description of deviation: From Log
Additional information: Optional
Write initials and date
Information from packs
Shipment no.: From Pack Slip

- The Temperature Excursion Report Form (TERF) - available in WebDCU™ Toolbox>Project Documents – submit for both storage and in transit excursions

What's inside the FASTEST kit?

Histidine Diluent box
Containing two 5.2 ml prefilled histidine syringes

rFVIIa Active or Placebo box
Containing two 5 mg vials of lyophilized drug

13 mm vial adapters
Each kit must have two vial adapters



Dosing/compounding card

The DUN boxes containing histidine and rFVIIa will be referred to as kit components in WebDCU.

FASTEST

Kit Component Boxes: Dosing/Compounding Card



FASTEST Study Drug Compounding Direction Card

Always use aseptic technique when compounding this product

If at any time the sterility of the study drug product is compromised discard the study drug kit and retrieved the second study drug kit from inventory.

1. Open the study drug kit and remove the study drug vials, prefilled histidine syringes, and vial adapters. Confirm all protective caps and seals are intact
2. Remove the cap from the study drug vials and disinfect the septum of each vial with a sterile isopropyl alcohol swab.
3. Open and attach the vial adapters to the study drug vial.
   - Holding the foil side of the packaging upwards and firmly pinch the side of the vial adapter through the packaging while removing the foil seal.
   - Keep a firm grip on the sides of the vial adapter through the packaging, invert the vial adapter, and press the adapter onto the vial with the spike end down
   - You will feel or hear the vial adapter snap into place.
   - Through the packaging confirm the vial adapter is securely attached
   - Discard the packaging
4. Repeat steps 2-3 for the second study drug vial
5. Assemble the prefilled histidine syringes by attaching the threaded end of the plunger rod to the plunger of the syringe barrel and turn the plunger rod clockwise to secure.
6. Remove the protective cap from the prefilled histidine syringe.
   - Do NOT remove the protective cap from the syringe before attaching the plunger rod.
7. Attach the syringe to the vial adapter and hold the assembled syringe/vial at a 45° angle and slowly inject the histidine solution.
   - The histidine must be added slowly at a 45° angle to prevent foaming
   - Foam should settle before dose is withdrawn
   - The study drug should be colorless and free of particulates
   - Gently swirl the assembled syringe/vial if drug does not dissolve immediately
   - *Drug concentration is 1mg/1mL at this step*
8. Repeat steps 5-7 to reconstitute both study drug vials
9. Obtain an appropriately sized syringe from local inventory and withdraw dose
10. Confirm correct dose is drawn, drug is colorless and free of particles
11. Administer study drug (IV push over 2-5 minutes). Use a dedicated line or flush line before and after administration with 0.9% sodium chloride.

V1

Compounding instruction page



FASTEST Dosing Table - Drug Concentration=1mg/1mL

Weight (kg)	Weight (lb)	Dose (mg)	Weight (kg)	Weight (lb)	Dose (mg)	Weight (kg)	Weight (lb)	Dose (mg)
25	55-56	2.0	59	128-130	4.7	92-93	203-204	7.4
26-27	57-59	2.1	60	131-133	4.8	94	205-207	7.5
28	60-61	2.2	61	134-136	4.9	95	208-210	7.6
29	62-64	2.3	62-63	137-138	5.0	96	211-213	7.7
30	65-67	2.4	64	139-141	5.1	97-98	214-215	7.8
31	68-70	2.5	65	142-144	5.2	99	216-218	7.9
32-33	71-72	2.6	66	145-147	5.3	100	219-221	8.0
34	73-75	2.7	67-68	148-149	5.4	101	222-224	8.1
35	76-79	2.8	69	150-152	5.5	102-103	225-226	8.2
36	79-81	2.9	70	153-155	5.6	104	227-229	8.3
37-38	82-83	3.0	71	156-158	5.7	105	230-232	8.4
39	84-86	3.1	72-73	159-160	5.8	106	233-235	8.5
40	87-89	3.2	74	161-163	5.9	107-108	236-237	8.6
41	90-92	3.3	75	164-166	6.0	109	238-240	8.7
42-43	93-94	3.4	76	167-169	6.1	110	241-243	8.8
44	95-97	3.5	77-78	170-171	6.2	111	244-246	8.9
45	98-100	3.6	79	172-174	6.3	112-113	247-248	9.0
46	101-103	3.7	80	175-177	6.4	114	249-251	9.1
47-48	104-105	3.8	81	178-180	6.5	115	252-254	9.2
49	106-108	3.9	82-83	181-182	6.6	116	255-257	9.3
50	109-111	4.0	84	183-185	6.7	117-118	258-259	9.4
51-52	112-114	4.1	85	186-188	6.8	119	260-262	9.5
53	115-116	4.2	86	189-191	6.9	120	263-265	9.6
54	117-119	4.3	87-88	192-193	7.0	121	266-268	9.7
55	120-122	4.4	89	194-196	7.1	122-123	269-270	9.8
56	123-124	4.5	90	197-199	7.2	124	271-273	9.9
57-58	125-127	4.6	91	200-202	7.3	≥ 125	≥ 274	10.0

Dosing Equation: dose (mg)=weight (kg) x 80 mcg/kg x mg/1,000 mcg
1lb = kg x 2.2 | 1kg = lb/2.2 | 1,000mcg = 1mg

V1

Dosing Chart (US and Canada) page

Two-sided card added to each kit

NIH StrokeNet
PREVENTION | TREATMENT | RECOVERY

FASTEST

Inside the shipment from Novo Nordisk
Inside the rFVIIa/placebo DUN Box



Inside the shipment from Novo Nordisk
Inside the Histidine DUN Box



NIH StrokeNet
PREVENTION | TREATMENT | RECOVERY

FASTEST

Accountability & Chain of Custody

- CPS with two enrolling locations provided with four kits; the CPS can determine how many study drug kits to store for each enrolling location; WebDCU™ will not provide this information.
- It is recommended to keep **two kits at each enrolling location**, so a back-up kit is available, if needed.
- CPSs will be responsible to complete the chain of custody form each time a study drug kit is transferred internally from one location to another.
- Chain of Custody and Accountability Logs serve as tracking documents to track the investigational product from the time it leaves the manufacturer until the time it is used by a subject, destroyed, or returned to the Canadian Central Blood Bank.

Don't break the chain!

- Sites are required to maintain study drug accountability records and temperature monitoring logs
  - Sites may use their institution's electronic inventory system or use the provided paper logs (WebDCU™ Toolbox>Project Documents)

Drug Accountability

Investigational Product (IP) Accountability Log
Trial: rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial Canadian Protocol Number 2020065801T

Site Number:	**Site PI:**
Health Canada Sponsor: Dr. Dowlatshahi, Ottawa Hospital Research Institute	**Site Coordinator:**

Instructions: *Each row is for the accountability of one study kit.*

Overall inventory on site			Subject level drug accountability					Drug destruction (if at subsite)		
Date received	Kit Code	Site personnel (initials/date)	Subject ID	Date dispensed	Total volume prepared (mL)	Total volume administered (mL)	Dispenser (initials/date)	# of vials destroyed	Date destructed	Site personnel (initials/date)

NIH StrokeNet PREVENTION | TREATMENT | RECOVERY

FASTEST

Chain of Custody

Investigational product (IP) Chain of Custody Log
Trial: rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial
Protocol Number: Canadian Protocol Number: 20200658-01T

Site Number:	**Site PI:**
Health Canada Sponsor: Dr. Dowlatshahi, Ottawa Hospital Research Insitute	**Site Coordinator:**

Instructions: *Any exchange of FASTEST Kits should be documented on this form*

Transition From *(Location of Medication Storage)*	**Transition To** *(Location of Medication Storage)*	**Date/Time**	**Received by (initials)**	**# of Kits**	**Kit Code(s)**	**The Study Kit/s is/are received in good condition (initials/date)**

Study Drug Dispensing Workflow

Notification of a potential subject

Select the study drug kit from inventory with the lowest study drug kit ID

- **No** randomization in WebDCU needed prior to study administration
- Bring to **room temperature** if needed

Compound study drug (video training next slide)

If not used immediately after reconstitution, store the suspension **in the vial with vial adapter and syringe still attached.** Store refrigerated (2-8°C) for 24 hours or at room temperature (below 25°C) for 6 hours. Do not freeze. Protect from light. After reconstitution, use only if product looks clear and colourless.

Once eligibility is confirmed

Follow institutional policies & procedures for entering emergency medicine order

Administer study drug

Eligibility is not confirmed

Used study drug kit box may be disposed appropriately, per institutional policy

Mark the study drug kit as destroyed in WebDCU

Resupply of study drug is triggered, Canadian Central Blood Bank will send replacement kit

Complete the **Subject Enrollment form** in WebDCU™ after administration as soon as possible (**within 6 hours**)

Used study drug kit box may be disposed appropriately

Retain the study drug kit box. Dispose of vials, syringes, and vial adapters appropriately, per institutional policy

Information need to document:

- *Date/time of study drug preparation*
- *Weight used for dosage*
- *Date/time of infusion start*
- *Dose administered*

Compounding Video

Please review and refer to the pharmacy compounding video for visual demonstration:

https://dcu.musc.edu/campus/ProjectTraining/FASTESTPharmacyCompounding.mp4

IMPORTANT

- The prefilled glass syringe is **compatible with a standard Luer-lock connector.**
- However, some needleless connectors for intravenous catheters are incompatible with the glass diluent syringes (for example, certain connectors with an internal spike, such as Clave®/MicroClave®, InVision-Plus®, InVision-Plus CS®, InVision-Plus® Junior®, Bionector®), and their use can damage the connector and affect administration.

IMPORTANT

We encourage sites to stock appropriately sized syringes from local inventory alongside the study drug kits, for example, a 10 ml syringe for two reasons:

1. To draw up the appropriate dose ***accurately***. The volume on the histidine syringe is measured in <u>0.5 ml increments</u>. However, according to the dosing table and administration instructions, drug is given in 0.1 ml increments
   - for example, for patient weight of 90 kg, per the dosing card, the dose administered should be 7.2 ml

2. To administer study drug through an incompatible needleless connector (refer to previous slide).

In these scenarios, once the study drug is reconstituted, leave the histidine syringe attached until it is ready for use. Note that 2 vials will usually be required. When the drug is ready to use, obtain a syringe of appropriate size from local inventory, remove the pre-filled histidine syringes from the study vials, and use the 'local' syringe to draw up the appropriate dose accurately.

Study Drug Requests

WebDCU™ study drug shipment requests will automatically be sent to the Central Canadian Blood Bank when:

- Sites released to receive study drug
- Subjects are randomized (complete Subject Enrollment form in WebDCU™ within **6 hours** of drug administration)
- Study drug damage
- Study drug expired
  - 7 days prior to the expiration of a study drug kit, CPSs will receive an automated email from WebDCU™ notifying them of the kit(s) in inventory expiring. CPSs will receive **this email daily until the expiring study drug kit is removed** from WebDCU™ inventory.

NIH StrokeNet
PREVENTION | TREATMENT | RECOVERY

FASTEST

Study Drug Kit Expiration

Study drug kit expiration dates are available in 2 locations:

- FASTEST study drug packing slip
- WebDCU™ (Drug Tracking Tab> Site Drug Kit Removing)
  - Will NOT be on study drug kit labels

Sites will receive emails from WebDCU™ and the Canadian Central Blood Bank when kits are nearing their expiration.

- Emails will contain instructions on how to handle expiring kits and when to expect replacement kits.
- Replacement kits will be sent before current inventory expirations to prevent CPSs from running out of study drug inventory.



FASTEST Investigational Product Packing Slip

Ship From:
Canada Pharmacy
501 Smyth Road, Transfusion Medicine Room M3604
Ottawa, ONK1H 8L6

Contact: Heather Maddison
Phone: 613-737-8899 x71605

Ship To:
WebDCU Test Site 2, Charleston, SC
, SC

Shipment Tracking Number: 2348-08/06/2021

FASTEST Investigational Product Shipping Contents

Site ID: 2348 Site Name: WebDCU Test Site 2, Charleston, SC

No.	Drug Kit Code	rFVIIa/Placebo Component Code	Histidine Component Code	Expiration Date	Shipping Date
1	60001	2370094	2371896	1/21/2022	8/6/2021

Generated by WebDCU on 8/6/2021 12:58:43 PM EST

Back to previous page

NIH StrokeNet
PREVENTION | TREATMENT | RECOVERY

FASTEST

Drug Kit Removing



NIH StrokeNet
PREVENTION | TREATMENT | RECOVERY

FASTEST

Study Drug Destruction & Return

Sites should follow their institutional policy regarding drug destruction protocol

The Canadian Central Blood Bank can accept returns for destruction if a CPS's institutional policy requires returning the damage or expired drug kits

Follow the steps below to return study drug to the Canadian Central Blood Bank

Study Drug Return Form must be completed and returned with the shipment

Available on WebDCU™ - Toolbox>Project Documents

Returns should be addressed and shipped to the Canadian Central Blood Bank via the CPS's preferred postal carrier

Return cost will be at the expense of the CPS

Package tracking information must be provided to Canadian Central Blood Bank via email

Temperature monitoring is NOT required for returns

Subject identifiers must be removed from returns

Study Drug Destruction & Return



Investigational product (IP) Return Form

Trial: rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial	Canadian Protocol Number: 20200658-01T

Instructions:

1. Notify the Canadian Central Blood Bank (fastestbloodbank@ohri.ca) of return date.
2. Complete all sections (except *Blood bank* section).
3. Sign and date this form.
4. Keep a copy of form for your records.
5. Enclose this form with study products and return via preferred shipping method to the Canadian Central Blood bank.
6. Ensure that study products are packed properly to prevent breakage and/or leakage.
7. Send tracking number/information to the blood bank.

Return Address:
Attn: Heather Maddison
The Ottawa Hospital – General Campus
Transfusion Medicine
501 Smyth Road,
Ottawa, ON K1H 8L6
Phone: 613.737.8899 x71605
Fax: 613-737-8281
Email: fastestbloodbank@ohri.ca

Site Number:	Site PI:
Health Canada Sponsor: Dr. Dowlatshahi, Ottawa Hospital Research Insitute	Site Coordinator:

Protocol Number	Kit Code	Full	Partial	Manufacturer	Lot Number	Comment(s)

Site Mailing Address	Study Personnel Name:	Contact Phone Number:
	Study Personnel Signature:	Date:

Canadian Central Blood Bank Use Only

Protocol Number/Study Product Name	Date Processed	Signature of Reviewing Official

Canadian version dated October 07 2021

Page _____ of _____

NIH StrokeNet
PREVENTION | TREATMENT | RECOVERY

FASTEST

When you think about **FASTEST** remember …….

- Prepare study drug as **FAST** as you can
  - prior to study drug administration, no randomization in WebDCU needed
- Complete the Subject Enrollment form in WebDCU as **FAST** as possible (within 6 hours post study drug administration) so that …
- Canadian Central Blood Bank can resupply you with study drug as **FAST** as they can.

NIH StrokeNet PREVENTION | TREATMENT | RECOVERY

FASTEST

Questions?

Please visit WebDCU™ for a copy of the FASTEST Study Drug Procedure Manual for Canada

Toolbox>Project Documents